CN103889426A - 用于口服的溶液 - Google Patents

用于口服的溶液 Download PDF

Info

Publication number
CN103889426A
CN103889426A CN201280051524.2A CN201280051524A CN103889426A CN 103889426 A CN103889426 A CN 103889426A CN 201280051524 A CN201280051524 A CN 201280051524A CN 103889426 A CN103889426 A CN 103889426A
Authority
CN
China
Prior art keywords
acid
solution
oral administration
compound
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280051524.2A
Other languages
English (en)
Chinese (zh)
Inventor
冈本绫子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to CN201711285346.0A priority Critical patent/CN107823131A/zh
Publication of CN103889426A publication Critical patent/CN103889426A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280051524.2A 2011-10-19 2012-10-19 用于口服的溶液 Pending CN103889426A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711285346.0A CN107823131A (zh) 2011-10-19 2012-10-19 用于口服的溶液

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548859P 2011-10-19 2011-10-19
US61/548,859 2011-10-19
PCT/JP2012/077668 WO2013058411A1 (en) 2011-10-19 2012-10-19 Solution for oral administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711285346.0A Division CN107823131A (zh) 2011-10-19 2012-10-19 用于口服的溶液

Publications (1)

Publication Number Publication Date
CN103889426A true CN103889426A (zh) 2014-06-25

Family

ID=47178263

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280051524.2A Pending CN103889426A (zh) 2011-10-19 2012-10-19 用于口服的溶液
CN201711285346.0A Pending CN107823131A (zh) 2011-10-19 2012-10-19 用于口服的溶液

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711285346.0A Pending CN107823131A (zh) 2011-10-19 2012-10-19 用于口服的溶液

Country Status (35)

Country Link
US (8) US20140303183A1 (enExample)
EP (1) EP2768508B1 (enExample)
JP (1) JP6077534B2 (enExample)
KR (1) KR101856283B1 (enExample)
CN (2) CN103889426A (enExample)
AR (1) AR088372A1 (enExample)
AU (2) AU2012326978B2 (enExample)
BR (1) BR112014009330A2 (enExample)
CA (1) CA2851999C (enExample)
CL (1) CL2014000967A1 (enExample)
CO (1) CO6950486A2 (enExample)
CY (1) CY1117794T1 (enExample)
DK (1) DK2768508T3 (enExample)
EA (2) EA201490812A1 (enExample)
ES (1) ES2583137T3 (enExample)
HR (1) HRP20160989T1 (enExample)
HU (1) HUE028869T2 (enExample)
IL (1) IL231988A (enExample)
IN (1) IN2014DN02987A (enExample)
JO (1) JO3190B1 (enExample)
LT (1) LT2768508T (enExample)
ME (1) ME02459B (enExample)
MX (1) MX347309B (enExample)
MY (1) MY169096A (enExample)
PH (1) PH12014500816A1 (enExample)
PL (1) PL2768508T3 (enExample)
PT (1) PT2768508T (enExample)
RS (1) RS54967B1 (enExample)
SG (1) SG11201401273SA (enExample)
SI (1) SI2768508T1 (enExample)
SM (1) SMT201600341B (enExample)
TW (2) TWI632921B (enExample)
UA (1) UA111506C2 (enExample)
WO (1) WO2013058411A1 (enExample)
ZA (1) ZA201402669B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116966140A (zh) * 2023-08-18 2023-10-31 四川阿赛斯生物科技有限公司 一种含有布瑞哌唑的口服溶液及其制备方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
RU2633635C1 (ru) * 2016-06-29 2017-10-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
RU2627423C1 (ru) * 2016-06-29 2017-08-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
WO2017095265A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
WO2017095266A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения (варианты)
JP6786240B2 (ja) * 2016-03-31 2020-11-18 小林製薬株式会社 粘性経口組成物
EP3582765B1 (en) * 2017-10-10 2021-04-28 Vertice Pharma, LLC Midodrine hydrochloride oral solution and uses thereof
JPWO2021029020A1 (enExample) * 2019-08-13 2021-02-18
JP2021115288A (ja) * 2020-01-28 2021-08-10 青葉化成株式会社 液状組成物および液状医療材料
CA3184425A1 (en) * 2020-06-30 2022-01-06 Mark C. Faulkner Compositions for controlling odor and itch and methods of and devices for administering same
JP2023532085A (ja) 2020-06-30 2023-07-26 ビレオ システムズ インコーポレイテッド 膣感染症を治療するための組成物及び方法
CN115192548A (zh) * 2021-04-13 2022-10-18 上海博志研新药物技术有限公司 一种布瑞哌唑口溶膜组合物、其制备方法及应用
CN115414322A (zh) * 2022-07-05 2022-12-02 杭州民生药物研究院有限公司 一种富马酸卢帕他定口服液体制剂及其制备工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155804A (zh) * 2005-04-14 2008-04-02 大塚制药株式会社 用于治疗精神疾病的哌嗪取代的苯并噻吩
CN101257890A (zh) * 2005-09-01 2008-09-03 巴克斯特国际公司 含有酸作为增溶剂的阿加曲班制剂
CN101848699A (zh) * 2007-10-31 2010-09-29 詹森药业有限公司 稳定的卡立氨酯儿科混悬剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420077A (en) * 1972-04-14 1976-01-07 Unilever Ltd Process for imparting or enhancing fresh cheese flavour in a food digital transmission systems
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
MXPA04010921A (es) * 2002-05-03 2005-05-27 Israel Inst Biolog Res Metodos y composiciones para el tratamietno de trastornos del sistema nervioso central y periferico y compuestos novedosos utiles para los mismos.
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
CN101198331B (zh) * 2005-06-13 2012-05-02 大日本住友制药株式会社 增溶化制剂
CA2659390A1 (en) * 2006-07-31 2008-02-07 Asubio Pharma Co., Ltd. Liquid preparation
JP2010539173A (ja) * 2007-09-17 2010-12-16 シェーリング コーポレイション サイクリン依存キナーゼ阻害化合物を含む製剤およびこの製剤を用いて腫瘍を処置する方法
AU2008302201A1 (en) * 2007-09-21 2009-03-26 Astrazeneca Ab Soluble dosage forms containing cephem derivatives suitable for parenteral administration
CN103025318B (zh) * 2010-08-24 2016-07-06 大塚制药株式会社 含有喹啉酮衍生物、和硅油和/或硅油衍生物的悬浮液和块状组合物
CN102119922A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以酸作为增溶剂的21(s)阿加曲班静脉注射液
AR085840A1 (es) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155804A (zh) * 2005-04-14 2008-04-02 大塚制药株式会社 用于治疗精神疾病的哌嗪取代的苯并噻吩
CN101257890A (zh) * 2005-09-01 2008-09-03 巴克斯特国际公司 含有酸作为增溶剂的阿加曲班制剂
CN101848699A (zh) * 2007-10-31 2010-09-29 詹森药业有限公司 稳定的卡立氨酯儿科混悬剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116966140A (zh) * 2023-08-18 2023-10-31 四川阿赛斯生物科技有限公司 一种含有布瑞哌唑的口服溶液及其制备方法

Also Published As

Publication number Publication date
HRP20160989T1 (hr) 2016-10-07
US20200171023A1 (en) 2020-06-04
MX2014004529A (es) 2014-08-01
AU2017213570A1 (en) 2017-08-31
ES2583137T3 (es) 2016-09-19
TW201330873A (zh) 2013-08-01
AU2012326978B2 (en) 2017-08-31
CO6950486A2 (es) 2014-05-20
ZA201402669B (en) 2015-09-30
TWI632921B (zh) 2018-08-21
KR20140083032A (ko) 2014-07-03
AU2012326978A1 (en) 2014-05-22
CA2851999C (en) 2020-01-07
MY169096A (en) 2019-02-18
LT2768508T (lt) 2016-09-12
PL2768508T3 (pl) 2016-12-30
NZ623523A (en) 2015-12-24
PH12014500816A1 (en) 2014-05-19
TWI679977B (zh) 2019-12-21
ME02459B (me) 2017-02-20
BR112014009330A2 (pt) 2017-04-11
IL231988A0 (en) 2014-05-28
HUE028869T2 (en) 2017-01-30
UA111506C2 (uk) 2016-05-10
US20210236483A1 (en) 2021-08-05
US20250099460A1 (en) 2025-03-27
CA2851999A1 (en) 2013-04-25
SI2768508T1 (sl) 2016-09-30
EA201490812A1 (ru) 2014-09-30
WO2013058411A1 (en) 2013-04-25
KR101856283B1 (ko) 2018-05-09
MX347309B (es) 2017-04-21
IN2014DN02987A (enExample) 2015-05-08
US20180271858A1 (en) 2018-09-27
PT2768508T (pt) 2016-08-17
DK2768508T3 (en) 2016-08-29
US20240009186A1 (en) 2024-01-11
JP2014530801A (ja) 2014-11-20
SMT201600341B (it) 2016-11-10
IL231988A (en) 2017-09-28
EP2768508B1 (en) 2016-07-06
SG11201401273SA (en) 2014-05-29
JO3190B1 (ar) 2018-03-08
TW201737916A (zh) 2017-11-01
AR088372A1 (es) 2014-05-28
EA202190445A2 (ru) 2021-08-31
US20170182036A1 (en) 2017-06-29
CL2014000967A1 (es) 2014-10-03
HK1196773A1 (zh) 2014-12-24
EP2768508A1 (en) 2014-08-27
US20140303183A1 (en) 2014-10-09
CN107823131A (zh) 2018-03-23
JP6077534B2 (ja) 2017-02-08
CY1117794T1 (el) 2017-05-17
US20160213665A1 (en) 2016-07-28
RS54967B1 (sr) 2016-11-30

Similar Documents

Publication Publication Date Title
CN103889426A (zh) 用于口服的溶液
CN1512884B (zh) 阿立哌唑口服溶液
CN109893502B (zh) 一种枸橼酸托法替布组合物及其制备方法
KR102391494B1 (ko) 몬테루카스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 안정성이 개선된 액상 제제 및 이의 제조방법
KR20150035273A (ko) 몬테루카스트 또는 그의 약제학적으로 허용 가능한 염, 및 산성 안정화제를 포함하는 안정성이 개선된 시럽 제제 및 그의 제조 방법
CN114173761B (zh) 包含乌地那非的药物组合物
US20170157108A1 (en) Liquid formulation comprising montelukast or pharmaceutically acceptable salt thereof and method for preparing same
JP5072748B2 (ja) アムロジピンの安定な液剤とゼリー剤
HK1196773B (en) Solution for oral administration
KR101669556B1 (ko) 몬테루카스트 또는 이의 약제학적으로 허용가능한 염의 경구투여용 액상제제
LU103368B1 (en) Pharmaceutical suspension of nilotinib
WO2013062497A1 (en) Liquid pharmaceutical formulations
TW201605464A (zh) 經安定化的去氨加壓素
JP2013512204A (ja) 液体医薬組成物
NZ623523B2 (en) Solution for oral administration
KR20200138556A (ko) 몬테루카스트 또는 그의 약제학적으로 허용가능한 염을 포함하는 시럽 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140625